phone (617) 481-4020
mail [email protected]
Contact
left-arrowBack to search

Internet-Based Lifestyle Intervention (iLIVE) to Eradicate Obese Frailty in Prostate Cancer Survivors

Clinicaltrials.gov ID: NCT06011499
db-list-check Status RECRUITING
b-loader Phase NA
b-people Age All Ages
b-bullseye-arrow Enrollments 250

Conditions

Prostate Carcinoma

Summary

This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity and frailty in men with prostate cancer who receive ADT.

Detailed Description

PRIMARY OBJECTIVE:

I. To test the effectiveness of a combined online weight loss plus resistance training intervention (iLIVE) on obese frailty in prostate cancer survivors (PCS) on ADT.

SECONDARY OBJECTIVES:

I. To understand the effect of iLIVE on health behaviors, physical functioning, and quality of life II. To understand facilitators and barriers to implementing iLIVE in clinical and community practice

OUTLINE: Patients are randomized to arm I or II. Key stakeholders are identified for implementation outcomes

ARM I: Patients receive online access to an interactive weight loss website and participate in online group based resistance training sessions (iLIVE) on study. Patients also use a Fitbit fitness tracker and Aria (registered trademark) smart scale while on study.

ARM II: Patients receive usual care with access to online survivorship and exercise recommendations and use a Fitbit fitness tracker and Aria (registered trademark) smart scale while on study.

Patients are followed for 6 months after completion of intervention.

Key stakeholders complete an interview while on study to assess barriers and facilitators to implementation of iLIVE into clinical practice.

Locations

1 location Found with status Recruiting

Status

  • RECRUITING

Contact Person

Principal Investigator

  • Kerri Winters-Stone

Eligibility Criteria

Inclusion Criteria:

* INTERVENTION PARTICIPANTS: Age 18 or older
* INTERVENTION PARTICIPANTS: Diagnosed with histologically confirmed prostate cancer
* INTERVENTION PARTICIPANTS: Received >= 6 months of ADT any time in the past 10 years
* INTERVENTION PARTICIPANTS: Completed radiotherapy, chemotherapy and/or surgery > 6 weeks prior to
* INTERVENTION PARTICIPANTS: No intent to start adjuvant chemotherapy or radiotherapy within 6 months of enrollment
* INTERVENTION PARTICIPANTS: Overweight or obese (BMI > 25 kg/m2 to BMI ≤ 50).
* INTERVENTION PARTICIPANTS: Evidence of frailty by meeting three or more of the following frailty criteria: weakness, slowness, fatigue, inactivity, and/or illness
* INTERVENTION PARTICIPANTS: Not currently engaging in structured diet or resistance strength training exercise program
* INTERVENTION PARTICIPANTS: Willing to be randomized into either study arm and adhere to study protocol
* INTERVENTION PARTICIPANTS: Home internet sufficient for videoconferencing
* INTERVENTION PARTICIPANTS: Signed informed consent
* IMPLEMENTATION PARTICIPANTS: Be a key stakeholder (i.e., healthcare provider or administrative, or intervention participant [completers, partial completers, or no participation])
* IMPLEMENTATION PARTICIPANTS: Verbal informed consent following receipt of an information sheet

Exclusion Criteria:

* INTERVENTION PARTICIPANTS: Unintentional weight loss > 5% within the last year
* INTERVENTION PARTICIPANTS: Contraindication to moderate intensity exercise
* INTERVENTION PARTICIPANTS: Health or medical condition that affects weight status/body composition (e.g., Cushing's syndrome, uncontrolled hyper-/hypo- thyroidism)
* INTERVENTION PARTICIPANTS: Active malignancy (other than non-melanoma skin cancer)
* INTERVENTION PARTICIPANTS: Not fluent in English and therefore incapable of answer survey questions, following directions during exercise or performance testing, and providing informed consent in English

Study Plan

Arm I (iLIVE)

EXPERIMENTAL

ARM I: Patients receive online access to an interactive weight loss website and participate in online group based resistance training sessions (iLIVE) on study. Patients also use a Fitbit fitness tracker and Aria smart scale while on study.

  • OTHER:

    Internet-Based Exercise Intervention

    Description:

    Participate in online supervised, group resistance training sessions (iLIVE)

  • OTHER:

    Internet-Based Diet Intervention

    Description:

    Receive online access to an interactive website with a series of weekly self-directed and interactive sessions on various topics associated with diet and weight loss (iLIVE)

Arm II (Usual care)

ACTIVE_COMPARATOR

Patients receive usual care with access to online survivorship and exercise recommendations and use a Fitbit fitness tracker and Aria (registered trademark) smart scale while on study.

  • OTHER:

    Education Intervention

    Description:

    Receive usual care receiving educational information about diet and exercise for cancer survivors

Outcome Measures

Primary Outcome Measures

Change in overweight/obesity

Time Frame: At baseline, 3 months, 6 months and 12 months

Change in sarcopenia

Time Frame: At baseline and 6 months

Change in slowness

Time Frame: At baseline, 3 months and 6 months

Change in weakness

Time Frame: At baseline, 3 months, and 6 months

Change in inactivity

Time Frame: At baseline, 3 months, 6 months, and 12 months

Change in frailty

Time Frame: At baseline, 3 months, 6 months, and 12 months

Secondary Outcome Measures

Change in health behaviors

Time Frame: At baseline, 3 months, 6 months, and 12 months

Change in physical functioning

Time Frame: At baseline, 3 months, 6 months, 12 months

Change in quality of life

Time Frame: At baseline, 3 months, 6 months, and 12 months

Timeline

  • Last Updated
    October 22, 2024
  • Start Date
    August 25, 2023
  • Today
    February 5, 2025
  • Completion Date ( Estimated )
    December 31, 2027

Similar Trials

A Randomised Controlled Trial to Evaluate the Impact of Complement Theory’s Live 1:1 Exercise ...
light-list-check RECRUITING light-blue-people 21 - 64 Years
A Dose Finding Study of Debio 4228 in Participants With Locally Advanced/Metastatic Prostate Cancer
light-list-check RECRUITING light-blue-people ≥ 18 Years
A Study of Mental Health Care in People with Cancer
light-list-check RECRUITING light-blue-people ≥ 65 Years